EDIT Editas Medicine Inc.

33.9
+1.2  (+4%)
Previous Close 32.7
Open 33.03
52 Week Low 14.01
52 Week High 39.96
Market Cap $2,110,949,813
Shares 62,269,906
Float 62,215,796
Enterprise Value $1,466,308,926
Volume 1,702,957
Av. Daily Volume 871,497
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
EDIT-301
Sickle Cell Disease
Phase 1
Phase 1
IND filing due by the end of 2020.
AGN-151587 (EDIT-101)
Leber Congenital Amaurosis type 10 (LCA10).
Phase 1/2
Phase 1/2
Phase 1/2 commencement of dosing announced March 4, 2020.

Latest News

  1. CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a decision in an interference between the University of California, the University of Vienna, Emmanuelle Charpentier (CVC) and the Broad Institute, Inc. (Broad) regarding certain Broad CRISPR/Cas9 patents Editas Medicine exclusively licenses. The USPTO granted Broad's motion for priority benefit while denying CVC priority benefit to its two earliest provisional patent applications. As a result, Broad will enter the priority phase of the interference as "Senior Party" while CVC remains the "Junior Party" for purposes of determining which entity was the…

    CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a decision in an interference between the University of California, the University of Vienna, Emmanuelle Charpentier (CVC) and the Broad Institute, Inc. (Broad) regarding certain Broad CRISPR/Cas9 patents Editas Medicine exclusively licenses. The USPTO granted Broad's motion for priority benefit while denying CVC priority benefit to its two earliest provisional patent applications. As a result, Broad will enter the priority phase of the interference as "Senior Party" while CVC remains the "Junior Party" for purposes of determining which entity was the first to invent the inventions at issue.

    "We are pleased with the U.S. Patent and Trademark Office's decision, granting Broad's motion for priority benefit. We look forward to the proceedings, and we remain confident in our foundational patent portfolio that we in-license from the Broad Institute. While these proceedings are ongoing and will take time, we believe the outcome will ultimately be positive for the Broad Institute and their innovative and fundamental work on CRISPR/Cas9 gene editing," said Cynthia Collins, President and Chief Executive Officer, Editas Medicine.

    The Broad patents continue to be valid and in force. Foundational claims covering the use of CRISPR/Cas9 for gene editing in eukaryotic cells have also issued to Broad as patents in each of the United States, Australia, Europe, Japan, China and other jurisdictions.

    Aboutimage desc for 49 Editas Medicine

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com

    Forward-Looking Statements

    This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,'' ‘‘believe,'' ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' ‘‘intend,'' ‘‘may,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘target,'' ‘‘should,'' ‘‘would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.  Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent with litigation, including patent interference proceedings; uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements.  These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future.  Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

    Contacts:
    Media
    Cristi Barnett
    (617) 401-0113 
    
    
    Investors
    Mark Mullikin
    (617) 401-9083
    

    Primary Logo

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:

    Citi's 15th Annual BioPharma Virtual Conference
    Panel: Innovation in Cell Therapy
    Date: Wednesday, September 9, 2020
    Time: 3:20 p.m. ET

    Wells Fargo 2020 Virtual Healthcare Conference
    Fireside Chat
    Date: Thursday, September 10, 2020
    Time: 10:40 a.m. ET

    Morgan Stanley 18th Annual Global Healthcare Conference
    Fireside Chat
    Date: Tuesday, September 15, 2020
    Time: 10:15 a.m. ET

    The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available…

    CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:

    Citi's 15th Annual BioPharma Virtual Conference

    Panel: Innovation in Cell Therapy

    Date: Wednesday, September 9, 2020

    Time: 3:20 p.m. ET

    Wells Fargo 2020 Virtual Healthcare Conference

    Fireside Chat

    Date: Thursday, September 10, 2020

    Time: 10:40 a.m. ET

    Morgan Stanley 18th Annual Global Healthcare Conference

    Fireside Chat

    Date: Tuesday, September 15, 2020

    Time: 10:15 a.m. ET

    The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.

    About Editas Medicine

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

    Investor Contact

    Mark Mullikin

    (617) 401-9083

    Media Contact

    Cristi Barnett

    (617) 401-0113

    Primary Logo

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for EDIT-301, an experimental, autologous cell medicine, being developed as a potentially best-in-class, durable medicine for sickle cell disease. The Company plans to file an investigational new drug application (IND) for EDIT-301 by the end of 2020.

    "The Editas team has a bold vision to unlock the potential of CRISPR to design and develop game-changing medicines. We are making tremendous progress towards this vision with the continued development of EDIT-301, a potentially transformative medicine for…

    CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for EDIT-301, an experimental, autologous cell medicine, being developed as a potentially best-in-class, durable medicine for sickle cell disease. The Company plans to file an investigational new drug application (IND) for EDIT-301 by the end of 2020.

    "The Editas team has a bold vision to unlock the potential of CRISPR to design and develop game-changing medicines. We are making tremendous progress towards this vision with the continued development of EDIT-301, a potentially transformative medicine for the treatment of sickle cell disease, and we are pleased to receive Rare Pediatric Disease designation from the FDA for this program," said Cynthia Collins, Chief Executive Officer, Editas Medicine.  "We know patients are counting on us, and this designation is a significant milestone for the program that highlights the serious, life-threatening manifestations of sickle cell disease."

    The FDA defines a rare pediatric disease as a serious or life-threating disease in which the serious or life-threatening disease manifestations primarily affect individuals aged from birth to 18 years. Pediatric diseases recognized as "rare" affect under 200,000 people in the United States. Under the FDA's Rare Pediatric Disease Designation and Voucher Programs, a sponsor who receives an approval for a drug or biologic for a "rare pediatric disease" may be eligible for a voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product.

    About Sickle Cell Disease

    Sickle cell disease is an inherited blood disorder caused by a mutation in the beta-globin gene that leads to polymerization of the sickle hemoglobin protein (HbS). In sickle cell disease, the red blood cells are misshapen, in a sickle shape instead of the disc shape. The abnormal shape causes the cells to block blood flow causing anemia, pain crises, organ failure, and early death. There are an estimated 100,000 people in the United States currently living with sickle cell disease. Fetal hemoglobin (HbF) protects against sickle cell disease by inhibiting HbS polymerization.

    About EDIT-301

    EDIT-301 is an experimental, autologous cell therapy medicine under investigation for the treatment of sickle cell disease. EDIT-301 is comprised of sickle patient CD34+ cells genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP) to edit the HBG1/2 promoter region in the beta-globin locus. Red blood cells derived from EDIT-301 CD34+ cells demonstrate a sustained increase in fetal hemoglobin (HbF) production, which has the potential to provide a durable treatment benefit for people living with sickle cell disease.

    Aboutimage desc for 49 Editas Medicine

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com

    Forward-Looking Statements

    This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,'' ‘‘believe,'' ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' ‘‘intend,'' ‘‘may,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘target,'' ‘‘should,'' ‘‘would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company's plans with respect to timing of filing an IND for EDIT-301 by the end of 2020. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.  Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements.  These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future.  Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

    Contacts:

    Media

    Cristi Barnett

    (617) 401-0113

    Investors

    Mark Mullikin

    (617) 401-9083

     

    Primary Logo

    View Full Article Hide Full Article
  4. Regained full control of ocular medicines under new agreement with AbbVie

    BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020

    Plan to file IND for EDIT-301 for sickle cell disease by end of 2020

    Strengthened balance sheet through equity offering raising $216 million in gross proceeds

    Cash, cash equivalents, and marketable securities of $599 million as of June 30, 2020

    CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2020.

    "I am extremely proud of our recent progress, as we remain on track with previously shared guidance despite…

    Regained full control of ocular medicines under new agreement with AbbVie

    BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020

    Plan to file IND for EDIT-301 for sickle cell disease by end of 2020

    Strengthened balance sheet through equity offering raising $216 million in gross proceeds

    Cash, cash equivalents, and marketable securities of $599 million as of June 30, 2020

    CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2020.

    "I am extremely proud of our recent progress, as we remain on track with previously shared guidance despite the unpredictable challenges presented by COVID-19," said Cynthia Collins, Chief Executive Officer of Editas Medicine. "Our lead program evaluating EDIT-101 for the treatment of Leber congenital amaurosis 10 has continued to advance with dosing resuming in the Phase 1/2 BRILLIANCE trial, further solidifying Editas as the leader in the field of in vivo gene editing. Substantial progress has also been made toward an IND filing for EDIT-301 this year, with recent data presented at EHA providing preclinical proof-of-concept for this potentially best-in-class cell medicine for sickle cell disease." 

    Ms. Collins continued, "Alongside the clinical and scientific advances made last quarter, we also executed on several corporate milestones to better position the Company as we expand our clinical-stage pipeline. To ensure the efficient advancement of our pioneering gene editing medicines, we strengthened our balance sheet with the closing of a common stock offering resulting in gross proceeds of approximately $216 million. Importantly, we also secured dedicated cGMP-compliant manufacturing space to facilitate the completion of IND-enabling studies and early stage clinical manufacturing for our engineered cell medicines including EDIT-301 for sickle cell disease and EDIT-201, an allogeneic NK cell medicine for solid tumors."

    Recent Achievements and Outlook

    In Vivo CRISPR Medicines 

    • Ocular Medicines

      Regained full control of ocular medicines

      Editas Medicine (Company) has terminated its 2017 agreement with Allergan, now part of AbbVie, and entered a new agreement with AbbVie that returns development and commercialization rights for ocular medicines to the Company. The Company plans to continue to advance ocular medicines including EDIT-101 for Leber congenital amaurosis 10 (LCA10).



    • EDIT-101 for LCA10

      Continuation of dosing in BRILLIANCE Phase 1/2 clinical trial

      Enrollment remains active and sites have reopened for dosing following a brief pause due to COVID-19. The study, which represents the first and only clinical trial to administer an in vivo CRISPR medicine, remains on track to complete dosing of the adult low-dose cohort (two patients) and dose at least one patient in the adult mid-dose cohort by the end of 2020.

    Engineered Cell Medicines 

    • EDIT-301 for Sickle Cell Disease and Beta-Thalassemia

      Preclinical data presented at EHA reinforces best-in-class potential

      Data presented at the 25th Congress of the European Hematology Association (EHA) showed that treatment with EDIT-301, which leverages the Company's proprietary Cas12a (Cpf1) enzyme to edit directly at the HBG1/2 promoter, resulted in long-term in vivo editing with elevated and pan-cellular fetal hemoglobin expression. The Company remains on track to file an investigational new drug application (IND) for EDIT-301 by the end of 2020.



    • EDIT-201 to Treat Solid Tumors

      Declared candidate and initiated IND-enabling studies for allogeneic NK cell medicine

      EDIT-201 is an allogeneic healthy-donor NK cell medicine for the treatment of solid tumors. Editas Medicine plans to present preclinical data on EDIT-201 at a scientific conference in the second half of 2020. The Company plans to file an IND for EDIT-201 in the second half of 2021.    

    Corporate

    • Offering of Common Stock

      Strengthened balance sheet with gross proceeds of approximately $216 million

      Editas Medicine closed an underwritten offering of 6,900,000 shares of its common stock at a public offering price of $31.25 per share, before deducting underwriter discounts and commissions and estimated offering expenses. This included 900,000 shares issued upon exercise in full by the underwriter of its option to purchase additional shares. All shares in the offering were sold by Editas Medicine.



    • Leadership

      Editas Medicine has appointed Gad Berdugo as Chief Business Officer. Mr. Berdugo will lead business and corporate development, alliance management, and strategic planning for the Company. He brings more than 25 years of business and corporate development experience, most recently serving as Chief Executive Officer of EpiVax Oncology, a precision cancer immunotherapy company that he co-founded in 2017. 



    • Manufacturing

      Editas Medicine established manufacturing agreements with Azzur Group and Catalent to support preclinical and clinical development of the Company's portfolio of in vivo CRISPR and engineered cell medicines, including EDIT-101, EDIT-201, and EDIT-301. Following the termination of the 2017 agreement with Allergan, the Company has entered into a transition services agreement to transfer certain manufacturing material and processes for EDIT-101 and EDIT-102 from Allergan to Editas Medicine. 
    • Intellectual Property

      On June 24, 2019, the U.S. Patent and Trademark Office declared an interference between certain CRISPR/Cas9 patent applications submitted by the University of California, the University of Vienna, and Emmanuelle Charpentier and certain patents issued to the Broad Institute, Inc. (Broad) that have been licensed to Editas Medicine.  Oral arguments in the interference took place on May 18, 2020. The Broad patents remain valid and in force. Foundational claims covering the use of CRISPR/Cas9 for gene editing in eukaryotic cells have issued and continue to issue to Broad as patents in the United States, Europe, Japan, and other jurisdictions.

       
    • Balance Sheet

      The Company expects that its existing cash, cash equivalents and marketable securities of $598.7 million at June 30, 2020, and anticipated interest income will enable it to fund its operating expenses and capital expenditures into 2023.                           

    Second Quarter for 2020 Financial Results

    Cash, cash equivalents, and marketable securities at June 30, 2020, were $598.7 million, compared to $415.0 million at March 31, 2020. The increase was largely due to the $203.7 million in net proceeds raised from the company's recent equity offering.

    For the three months ended June 30, 2020, net loss attributable to common stockholders was $23.6 million, or $0.43 per share, compared to $33.8 million, or $0.69 per share, for the same period in 2019.

    • Collaboration and other research and development revenues were $10.7 million for the three months ended June 30, 2020, compared to $2.3 million for the same period in 2019. The $8.4 million increase was primarily attributable to $7.6 million in cash revenues received in connection with an out-license agreement and $0.8 million in non-cash revenue earned under our ongoing collaborations.
    • Research and development expenses increased by $4.4 million, to $28.0 million for the three months ended June 30, 2020, from $23.6 million for the same period in 2019. The $4.4 million increase was primarily attributable to fees incurred related to licensing and sublicensing activities, research personnel growth to support our programs as well as our expansion of the development organization and facilities These increases were partially offset by a decrease in process and platform expenses and share-based compensation.



    • General and administrative expenses decreased by $0.3 million to $14.1 million for the three months ended June 30, 2020, from $14.4 million for the same period in 2019. The $0.3 million decrease was primarily attributable to a decrease in the expense for professional service expenses and patent related fees which was partially offset by an increase is costs related to the hiring of key executives in the second half of 2019 and into 2020.

    Upcoming Events

    Editas Medicine plans to participate in the following scientific and medical conferences:

    • Society for Immunotherapy of Cancer 35th Annual Meeting, November 10-15, Virtual.

    Editas Medicine plans to participate in the following investor events:

    • Citi's 15th Annual BioPharma Conference, September 9-10, Virtual;
    • 2020 Wells Fargo Healthcare Conference, September 9-10, Virtual; and
    • Morgan Stanley 18th Annual Global Healthcare Conference, September 14-18, Virtual.

    Conference Call



    The Editas Medicine management team will host a conference call and webcast today at 5:00 p.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2020.  To access the call, please dial (844) 348-3801 (domestic) or (213) 358-0955 (international) and provide the passcode 9185596.  A live webcast of the call will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com  and a replay will be available approximately two hours after its completion.

    About Editas Medicine

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

    About EDIT-101

    EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10). EDIT-101 is administered via a subretinal injection using the proprietary Staphylococcus aureus Cas9 (SaCas9) enzyme, which can be packaged in a single adeno-associated virus (AAV) to deliver the gene editing machinery to photoreceptor cells. EDIT-101 is the first in vivo CRISPR medicine administered to humans.

    About EDIT-201

    EDIT-201 is an experimental, allogeneic natural killer (NK) cell medicine under investigation for the treatment of solid tumor cancers. EDIT-201 is comprised of NK cells derived from pooled healthy donor blood and genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP).

    About EDIT-301

    EDIT-301 is an experimental, autologous cell therapy medicine under investigation for the treatment of sickle cell disease. EDIT-301 is comprised of sickle patient CD34+ cells genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP) to edit the HBG1/2 promoter region in the beta-globin locus. Red blood cells derived from EDIT-301 CD34+ cells demonstrate a sustained increase in fetal hemoglobin (HbF) production, which has the potential to provide a durable treatment benefit for people living with sickle cell disease.

    Forward-Looking Statements

    This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,'' ‘‘believe,'' ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' ‘‘intend,'' ‘‘may,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘target,'' ‘‘should,'' ‘‘would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company's plans with respect to timing of dosing in and updates related to the Phase 1/2 BRILLIANCE clinical trial for EDIT-101, filing an IND for EDIT-301 by the end of 2020, and filing an IND for EDIT-201 in the second half of 2021. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. Those risks and uncertainties include, among other things, that the Company's expectations regarding the effects of COVID-19 may be incorrect, that data from the Company's development programs may not support registration or further development of its potential medicines due to safety, efficacy or other reasons, and other risks listed under "Risk Factors" included in the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future.  Any forward-looking statements contained in this press release represent Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

    EDITAS MEDICINE, INC. 
    Condensed Consolidated Statements of Operations 
    (unaudited) 
    (amounts in thousands, except per share and share data) 
      
      Three Months Ended  
      June 30,  
      2020  2019  
    Collaborationimage desc for 40 and other research and development revenues $10,749  $ 2,330  
    Operating expenses:       
    Researchimage desc for 41 and development  28,007   23,565  
    General and administrative  14,081   14,414  
    Totalimage desc for 42 operating expenses  42,088   37,979  
    Operatingimage desc for 44 loss  (31,339)  (35,649) 
    Other income, net:       
    Other income (expense), net  7,175   (68) 
    Interest income, net  592   1,931  
    Total other income, net  7,767   1,863  
    Net loss $(23,572) $(33,786) 
    Net loss per share basic and diluted $(0.43) $(0.69) 
    Weighted-average common shares outstanding, basic and diluted  55,346,052   49,070,574  



    EDITAS MEDICINE, INC.
    Selected Condensed Consolidated Balance Sheet Items
    (unaudited)
    (amounts in thousands)
             
       June 30, Decemberimage desc for 46 31, 
       2020 2019 
           
          
    Cash, cash equivalents, and marketable securities $598,720 $457,140 
    Working capital  541,976  403,881 
    Total assets  655,481  508,885 
    Deferredimage desc for 47 revenue, net of current portion 138,406  163,207 
    Total stockholders' equity  426,772  262,437 

    Investor Contact

    Mark Mullikin

    (617) 401-9083

    Media Contact

    Cristi Barnett

    (617) 401-0113

    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10, which were previously shared within a strategic research and development alliance with Allergan, which has since been acquired by AbbVie. Editas Medicine and AbbVie have terminated the original agreement and entered into a new agreement.

    "Allergan has been an excellent partner in helping advance EDIT-101 and our pipeline of gene editing medicines for people living with serious ocular diseases," said Cynthia Collins, Chief Executive…

    CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10, which were previously shared within a strategic research and development alliance with Allergan, which has since been acquired by AbbVie. Editas Medicine and AbbVie have terminated the original agreement and entered into a new agreement.

    "Allergan has been an excellent partner in helping advance EDIT-101 and our pipeline of gene editing medicines for people living with serious ocular diseases," said Cynthia Collins, Chief Executive Officer, Editas Medicine. "We are pleased to regain full operating control of our ocular programs, including EDIT-101, the first in vivo CRISPR medicine to be administered to patients, and we look forward to developing and commercializing these transformative ocular medicines."

    Collins continued, "We are currently focused on advancing EDIT-101 with dosing resumed in the Phase 1/2 BRILLIANCE clinical trial. We remain on track to complete dosing of the adult low-dose cohort and to dose at least one patient of the adult mid-dose cohort by the end of this year. We look forward to sharing additional updates from BRILLIANCE clinical trial and other medicines in development in our ocular program later this year."

    J.P. Morgan Securities LLC is serving as exclusive financial advisor to Editas Medicine.

    Aboutimage desc for 49 Editas Medicine

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

    About EDIT-101

    EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10). EDIT-101 is administered via a subretinal injection using the proprietary Staphylococcus aureus Cas9 (SaCas9) enzyme, which can be packaged in a single adeno-associated virus (AAV) to deliver the gene editing machinery to photoreceptor cells. EDIT-101 is the first in vivo CRISPR medicine administered to humans.

    Forward-Looking Statements

    This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,'' ‘‘believe,'' ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' ‘‘intend,'' ‘‘may,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘target,'' ‘‘should,'' ‘‘would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, including the Company's expectations regarding the timing of dosing in and updates related to the Phase 1/2 BRILLIANCE clinical trial. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.  Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements.  These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future.  Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

    Contacts:

    Media

    Cristi Barnett

    (617) 401-0113

    Investors

    Mark Mullikin

    (617) 401-9083

    Primary Logo

    View Full Article Hide Full Article
View All Editas Medicine Inc. News